1-12 of 12
Matt Coffey
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

Steffan T. Nawrocki, Julian Olea, Claudia Villa Celi, Homa Dadrastoussi, Kaijin Wu, Denice Tsao-Wei, Anthony Colombo, Matt Coffey, Eduardo Fernandez Hernandez, Xuelian Chen, Gerard J. Nuovo, Jennifer S. Carew, Ann F. Mohrbacher, Paul Fields, Peter Kuhn, Imran Siddiqi, Akil Merchant, Kevin R. Kelly
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5087–5103.
https://doi.org/10.1158/1078-0432.CCR-23-0229
Published: 15 December 2023
View article titled, Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
Open the PDF for Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial in another window
Includes: Supplementary data
Journal Articles

Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study

Devalingam Mahalingam, Grey A. Wilkinson, Kevin H. Eng, Paul Fields, Patrick Raber, Jennifer L. Moseley, Karol Cheetham, Matt Coffey, Gerard Nuovo, Pawel Kalinski, Bin Zhang, Sukeshi Patel Arora, Christos Fountzilas
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (1): 71–81.
https://doi.org/10.1158/1078-0432.CCR-19-2078
Published: 03 January 2020
View article titled, Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
Open the PDF for Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors

Victoria Roulstone, Khurum Khan, Hardev S. Pandha, Sarah Rudman, Matt Coffey, George M. Gill, Alan A. Melcher, Richard Vile, Kevin J. Harrington, Johann de Bono, James Spicer
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (6): 1305–1312.
https://doi.org/10.1158/1078-0432.CCR-14-1770
Published: 12 March 2015
View article titled, Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors
Open the PDF for Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Eleni M. Karapanagiotou, Victoria Roulstone, Katie Twigger, Mercel Ball, MaryAnne Tanay, Chris Nutting, Kate Newbold, Martin E. Gore, James Larkin, Konstantinos N. Syrigos, Matt Coffey, Brad Thompson, Karl Mettinger, Richard G. Vile, Hardev S. Pandha, Geoff D. Hall, Alan A. Melcher, John Chester, Kevin J. Harrington
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (7): 2080–2089.
https://doi.org/10.1158/1078-0432.CCR-11-2181
Published: 01 April 2012
View article titled, Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
Open the PDF for Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer

Martijn P. Lolkema, Hendrik-Tobias Arkenau, Kevin Harrington, Patricia Roxburgh, Rosemary Morrison, Victoria Roulstone, Katie Twigger, Matt Coffey, Karl Mettinger, George Gill, T.R. Jeffry Evans, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (3): 581–588.
https://doi.org/10.1158/1078-0432.CCR-10-2159
Published: 01 February 2011
View article titled, A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
Open the PDF for A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer in another window
Journal Articles

Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers

Kevin J. Harrington, Eleni M. Karapanagiotou, Victoria Roulstone, Katie R. Twigger, Christine L. White, Laura Vidal, Debbie Beirne, Robin Prestwich, Kate Newbold, Merina Ahmed, Khin Thway, Christopher M. Nutting, Matt Coffey, Dean Harris, Richard G. Vile, Hardev S. Pandha, Johann S. DeBono, Alan A. Melcher
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (11): 3067–3077.
https://doi.org/10.1158/1078-0432.CCR-10-0054
Published: 31 May 2010
View article titled, Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers
Open the PDF for Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers in another window
Includes: Supplementary data
Journal Articles

Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma

Hardev S. Pandha, Lucy Heinemann, Guy R. Simpson, Alan Melcher, Robin Prestwich, Fiona Errington, Matt Coffey, Kevin J. Harrington, Richard Morgan
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6158–6166.
https://doi.org/10.1158/1078-0432.CCR-09-0796
Published: 30 September 2009
View article titled, Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma
Open the PDF for Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma in another window
Journal Articles

Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2

Timothy Kottke, Jill Thompson, Rosa Maria Diaz, Jose Pulido, Candice Willmon, Matt Coffey, Peter Selby, Alan Melcher, Kevin Harrington, Richard G. Vile
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (2): 561–569.
https://doi.org/10.1158/1078-0432.CCR-08-1688
Published: 15 January 2009
View article titled, Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2
Open the PDF for Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2 in another window
Journal Articles

A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

Laura Vidal, Hardev S. Pandha, Timothy A. Yap, Christine L. White, Katie Twigger, Richard G. Vile, Alan Melcher, Matt Coffey, Kevin J. Harrington, Johann S. DeBono
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7127–7137.
https://doi.org/10.1158/1078-0432.CCR-08-0524
Published: 03 November 2008
View article titled, A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer
Open the PDF for A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer in another window
Journal Articles

Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy

Katie Twigger, Laura Vidal, Christine L. White, Johann S. De Bono, Shreerang Bhide, Matt Coffey, Brad Thompson, Richard G. Vile, Lucy Heinemann, Hardev S. Pandha, Fiona Errington, Alan A. Melcher, Kevin J. Harrington
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (3): 912–923.
https://doi.org/10.1158/1078-0432.CCR-07-1400
Published: 01 February 2008
View article titled, Enhanced <em>In vitro</em> and <em>In vivo</em> Cytotoxicity of Combined Reovirus and Radiotherapy
Open the PDF for Enhanced <em>In vitro</em> and <em>In vivo</em> Cytotoxicity of Combined Reovirus and Radiotherapy in another window
Includes: Supplementary data
Journal Articles

Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus

Jian Qiao, Hongxun Wang, Timothy Kottke, Christine White, Katie Twigger, Rosa Maria Diaz, Jill Thompson, Peter Selby, Johann de Bono, Alan Melcher, Hardev Pandha, Matt Coffey, Richard Vile, Kevin Harrington
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (1): 259–269.
https://doi.org/10.1158/1078-0432.CCR-07-1510
Published: 02 January 2008
View article titled, Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus
Open the PDF for Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus in another window
Journal Articles

Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals: Racine and Nonhuman Primates

Wen Qing Yang, Xueqing Lun, Cheryl Ann Palmer, M. Elizabeth Wilcox, Huong Muzik, Zhong Qiao Shi, Richard Dyck, Matt Coffey, Brad Thompson, Mark Hamilton, Sandra G. Nishikawa, Penny M. A. Brasher, Kevin Fonseca, David George, N. Berry Rewcastle, Randal N. Johnston, Doug Stewart, Patrick W. K. Lee, Donna L. Senger, Peter A. Forsyth
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (24): 8561–8576.
https://doi.org/10.1158/1078-0432.CCR-04-0940
Published: 28 December 2004
View article titled, Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals: <subtitle>Racine and Nonhuman Primates</subtitle>
Open the PDF for Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals: <subtitle>Racine and Nonhuman Primates</subtitle> in another window